Anti-Mouse CTLA-4 Monoclonal Antibodies for Flow Cytometry

PA007501.m2b: Recombinant Anti-mouse CTLA-4 Monoclonal Antibody (Clone: 9D9), Mouse IgG2b Kappa

Recombinant Mouse IgG2b Monoclonal Antibody. 
Clone: 9D9.
Isotype:  Mouse IgG2b Kappa.
Source: The anti-mouse CTLA-4 monoclonal antibody (clone: 9D9) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant 9D9 antibody specifically binds to mouse CTLA-4 protein.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F). 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007501.h1Fs: Recombinant Anti-mouse CTLA-4 Monoclonal Antibody (Clone: 9D9), Human IgG1 Fc Silent Kappa

Recombinant Human IgG1 Monoclonal Antibody with Fc silent mutation. 
Clone: 9D9.
Isotype: Human IgG1 kappa.
Source: The anti-mouse CTLA-4 monoclonal antibody (clone: 9D9) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant 9D9 antibody specifically binds to mouse CTLA-4 protein.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F). 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007730.m2b-b: Biotinylated Recombinant Anti-mouse CTLA-4 Monoclonal Antibody (Clone: 9D9), Mouse IgG2b Kappa

Recombinant mouse IgG2b monoclonal antibody with site-directed biotinylation through the Avi tag at the C-terminus of the antibody heavy chain.
Clone: 9D9.
Isotype:  Mouse IgG2b Kappa.
Source: The site-directed biotinylated anti-mouse CTLA-4 monoclonal antibody (clone: 9D9) was produced in mammalian cells.
Conjugation: Biotin-conjugated.
Specificity/Sensitivity: The site-directed biotinylated recombinant 9D9 antibody specifically binds to mouse CTLA-4 protein.
Applications: Flow cytometry (FC) with various dye conjugation through streptavidin; conjugation to streptavidin agarose beads or streptavidin magnetic beads.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The 9D9 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of anti-mouse CTLA-4 antibody for Flow Cytometry (Clone: 9D9):

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma.
Simpson, T. R., et al. J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130091. PMID: 23878181
The study investigates the mechanism of anti-CTLA-4 therapy using the 9D9 monoclonal antibody in a B16 melanoma mouse model. Tumor-infiltrating lymphocytes were isolated from B16 tumors 7 days after the final dose of anti-CTLA-4 mAb and stained with fluorescently conjugated antibodies against CD4, CD25, CTLA-4 (clone 9D9), FoxP3, CD103, CD8, and CD45.1. Flow cytometry, performed on a modified FACSCanto II cytometer and analyzed with FlowJo software, showed that Tregs were gated as CD4+ FoxP3+ tumor-infiltrating lymphocytes, with the frequency of CTLA-4+ Tregs determined. Anti-CTLA-4 therapy significantly increased CD8+ T cell infiltration in tumors, highlighting the Fc-dependent depletion of regulatory T cells as a key factor in therapeutic efficacy.
Tags: activity of 9D9 antibody; function of 9D9 antibody

Anti-CTLA-4 therapy broadens the melanoma-reactive CD4+ T cell response.
Quezada, S. A., et al. Oncoimmunology. 2014;3(5):e29032. doi: 10.4161/onci.29032. PMID: 24828551
This study explores the effects of anti-CTLA-4 therapy using the 9D9 monoclonal antibody on melanoma-reactive CD4+ T cells. Splenocytes were harvested and stained with fluorescently conjugated antibodies against CD4, CD8, CD25, CD44, CTLA-4 (clone 9D9), and PD-1 for flow cytometry analysis. Tetramer staining identified melanoma-specific CD4+ T cells, revealing a 3-fold increase in their frequency following anti-CTLA-4 treatment. Polyfunctional cytokine production was assessed via intracellular staining, demonstrating that anti-CTLA-4 therapy enhances the melanoma-reactive CD4+ T cell response.
Tags: 9D9 antibody for flow cytometry; 9D9 mAb

Flow cytometric analysis of CTLA-4 blockade effects using 9D9 antibody.
Arina, A., et al. Blood. 2015 Nov 26;126(23):1089. doi: 10.1182/blood.V126.23.1089.1089. PMID: 26490021
This research evaluates the effects of CTLA-4 blockade on NK cells using the 9D9 monoclonal antibody. NK cells were stained with antibodies against NKp46, CD3, CD69, and CTLA-4 (clone 9D9) for flow cytometry to assess activation post-CTLA-4 blockade. Peripheral blood mononuclear cells were isolated from treated mice, revealing increased CTLA-4 expression on NK cells after anti-PD-1 therapy. Combination blockade with anti-CTLA-4 and anti-PD-1 enhanced NK cell degranulation, indicating a synergistic effect in cancer immunotherapy.
Tags: 9D9 mAb for flow cytometry; 9D9 antibody for cancer research

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Wei, S. C., et al. Cell Res. 2018 Mar;28(4):445-461. doi: 10.1038/s41422-018-0011-0. PMID: 29453335
This study reappraises CTLA-4 checkpoint blockade using the 9D9 monoclonal antibody. T cells were surface-stained with antibodies against CD4, CD8, CTLA-4 (clone 9D9), and PD-1 for flow cytometric analysis to quantify exhausted T cell populations. Tumor-infiltrating lymphocytes were dissociated and stained ex vivo, showing that CTLA-4 blockade reduced Treg suppressive function in vitro. Combination with PD-1 blockade synergistically enhanced T cell proliferation, underscoring the potential of dual checkpoint inhibition in cancer immunotherapy.
Tags: 9D9 monoclonal antibody; 9D9 antibody

CTLA-4 expression on activated T cells by flow cytometry with clone 9D9.
Egen, J. G., et al. Immunity. 2006 Jun;24(6):803-14. doi: 10.1016/j.immuni.2006.04.009. PMID: 16751384
This study examines CTLA-4 expression on activated T cells using the 9D9 monoclonal antibody. Activated T cells were stained with PE-conjugated anti-mouse CTLA-4 (clone 9D9), revealing rapid upregulation of CTLA-4 within 24 hours of activation via flow cytometry. CD4+ T cells from OT-II mice were stimulated with OVA peptide, showing CTLA-4 internalization post-stimulation. Blockade with anti-CTLA-4 enhanced T cell expansion, demonstrating the role of CTLA-4 in regulating T cell responses in animal models.
Tags: 9D9 antibody mouse dose range; 9D9 mAb for animal model

For more references about anti-mouse CTLA-4 antibody for Flow Cytometry (Clone: 9D9), please contact our scientific support team with message@sydlabs.com.

Background

The 9D9 antibody blocks the mouse cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells.

Syd Labs provides the following in vivo grade recombinant anti-mouse CTLA-4 monoclonal antibodies:
Recombinant Anti-mouse CTLA-4 monoclonal antibody (Clone: 9D9)
Recombinant Anti-mouse CTLA-4 (CD152) monoclonal antibody (Clone: UC10-4F10-11)

Syd Labs provides the following recombinant anti-mouse CTLA-4 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CTLA-4 monoclonal antibody (Clone: 9D9) for flow cytometry

Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Recombinant CTLA-4 Proteins:
Biotinylated Human CTLA-4 Protein
Cynomolgus CTLA-4 Protein
Human CTLA-4 Protein